溴尿嘧啶
化学
表观遗传学
乳腺癌
癌症研究
小分子
癌症
癌细胞
药物发现
药理学
计算生物学
生物化学
内科学
生物
医学
基因
作者
Jon J. Winter-Holt,Catherine Bardelle,Elisabetta Chiarparin,Ian L. Dale,Paul R. J. Davey,Nichola L. Davies,Christopher R. Denz,Shaun M. Fillery,Carine M. Guerot,Fujin Han,Samantha J. Hughes,Meghana M. Kulkarni,Zhaoqun Liu,Alexander G. Milbradt,Thomas A. Moss,Huijun Niu,Joe Sahil Patel,Alfred A. Rabow,Marianne Schimpl,Junjie Shi
标识
DOI:10.1021/acs.jmedchem.1c01871
摘要
ATAD2 is an epigenetic bromodomain-containing target which is overexpressed in many cancers and has been suggested as a potential oncology target. While several small molecule inhibitors have been described in the literature, their cellular activity has proved to be underwhelming. In this work, we describe the identification of a novel series of ATAD2 inhibitors by high throughput screening, confirmation of the bromodomain region as the site of action, and the optimization campaign undertaken to improve the potency, selectivity, and permeability of the initial hit. The result is compound 5 (AZ13824374), a highly potent and selective ATAD2 inhibitor which shows cellular target engagement and antiproliferative activity in a range of breast cancer models.
科研通智能强力驱动
Strongly Powered by AbleSci AI